← Back to Search

NMDA Receptor Antagonist

Ketamine for Chronic Lower Back Pain and Depression

Phase 2
Waitlist Available
Led By Victoria D Powell, MD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Veterans with self-report of moderate to severe, high impact chronic low back pain (defined as 4/10 in severity via NRS, present 3 months on most days) and associated pain interference (defined as T-score 60 on the PROMIS Pain Interference measure), and current significant depressive symptoms (defined as a score 11 on the Quick Inventory of Depressive Symptoms - Self Report (QIDS-SR))
Medically stable (no hospitalizations in the past month lasting 3 days)
Must not have
Known elevated intracranial pressure, cerebral arterial aneurysm, or elevated intraocular pressure
Inability to speak English due to the narrative intervention being conducted in English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up visits 1-7 or weekly (whichever is more frequent); visit 8 (1 month follow up), visit 9 (3 month follow up)
Awards & highlights

Summary

"This trial is testing if ketamine infusions followed by a brief behavioral intervention are feasible, acceptable, and safe for Veterans with chronic low back pain and depression."

Who is the study for?
This trial is for veterans who have long-term lower back pain paired with depression. It's a pilot study, which means it's an early test to see if the approach works well and is safe.
What is being tested?
The study tests ketamine infusions (a type of medication that can affect mood and pain) followed by a short counseling session. The goal is to see if this combo helps more than usual care or just talking about one's life story.
What are the potential side effects?
Ketamine can cause side effects like changes in blood pressure, nausea, dizziness, mood swings, or hallucinations. The severity varies from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a veteran with chronic low back pain, it interferes with my daily life, and I feel significantly depressed.
Select...
I haven't been hospitalized for 3 days or more in the last month.
Select...
My pain or depression medication has been the same for the last 4 weeks.
Select...
I don't plan any new treatments for back pain or depression except physical therapy.
Select...
I have someone to drive me home after ketamine treatments.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have high pressure in my brain, aneurysm, or high eye pressure.
Select...
I cannot participate because I do not speak English.
Select...
I do not have a history of severe liver disease or unstable heart conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~visits 1-7 or weekly (whichever is more frequent); visit 8 (1 month follow up), visit 9 (3 month follow up)
This trial's timeline: 3 weeks for screening, Varies for treatment, and visits 1-7 or weekly (whichever is more frequent); visit 8 (1 month follow up), visit 9 (3 month follow up) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Pain intensity (Numeric Rating Scale)
Other outcome measures
Acceptability
Catastrophizing (Catastrophizing Subscale from the Coping Strategies Questionnaire (CSQ-CAT))
Cognitive Flexibility (Cognitive Flexibility Scale (CFS))
+16 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Open label, single arm pilotExperimental Treatment2 Interventions
Initial phase: A small open-label, single arm pilot study (n=5) will be conducted to develop and assess initial feasibility of study procedures and obtain participant feedback through semi-structured exit interviews. All participants in this open-label single arm pilot will receive the intervention (ketamine infusions followed by the brief behavioral intervention). There will be no control condition, randomization, or blinding.
Group II: Intervention + Minimally Enhanced Usual CareExperimental Treatment3 Interventions
Second phase: Intervention arm of a single-blind, two-arm, pilot feasibility randomized controlled trial (RCT) (n=44, 22 per arm) which will (a) assess feasibility benchmarks and (b) collect outcome data that will be used to calculate sample size to power a larger RCT. Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression.
Group III: Minimally Enhanced Usual Care OnlyActive Control2 Interventions
Second phase: Control arm of a single-blind, two-arm, pilot feasibility randomized controlled trial (RCT) (n=44, 22 per arm) which will (a) assess feasibility benchmarks and (b) collect outcome data that will be used to calculate sample size to power a larger RCT. Minimally Enhanced Usual Care will consist of educational reading materials regarding chronic back pain and depression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine hydrochloride
2022
Completed Phase 4
~40

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,628 Previous Clinical Trials
3,325,935 Total Patients Enrolled
77 Trials studying Depression
20,689 Patients Enrolled for Depression
Victoria D Powell, MDPrincipal InvestigatorVA Ann Arbor Healthcare System, Ann Arbor, MI
~29 spots leftby Dec 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top